The present invention relates to a method of treating disorders associated
with the .alpha..sub.2.delta. voltage-gated calcium channel ligand,
comprising the administration of compounds of formula (I), 1
or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof.
